vs
FIRST FINANCIAL CORP（THFF）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是FIRST FINANCIAL CORP的1.8倍（$127.1M vs $70.5M），再鼎医药同比增速更快（17.1% vs 14.1%），FIRST FINANCIAL CORP自由现金流更多（$86.4M vs $-26.7M），过去两年FIRST FINANCIAL CORP的营收复合增速更高（20.8% vs 20.8%）
第一美国金融公司是一家美国金融服务企业，主营为房地产与抵押贷款行业提供产权保险以及结算服务，深耕相关金融领域，是该细分赛道具备专业能力的服务提供商。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
THFF vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$70.5M
营收增速更快
ZLAB
高出3.0%
14.1%
自由现金流更多
THFF
多$113.1M
$-26.7M
两年增速更快
THFF
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $70.5M | $127.1M |
| 净利润 | $21.5M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 37.4% | -54.6% |
| 净利率 | 30.4% | — |
| 营收同比 | 14.1% | 17.1% |
| 净利润同比 | 32.1% | — |
| 每股收益（稀释后） | $1.81 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收THFFZLAB
| Q4 25 | $70.5M | $127.1M | ||
| Q3 25 | $65.8M | $115.4M | ||
| Q2 25 | $63.1M | $109.1M | ||
| Q1 25 | $62.5M | $105.7M | ||
| Q4 24 | $61.8M | $108.5M | ||
| Q3 24 | $58.4M | $101.8M | ||
| Q2 24 | $49.2M | $100.1M | ||
| Q1 24 | $48.4M | $87.1M |
净利润THFFZLAB
| Q4 25 | $21.5M | — | ||
| Q3 25 | $20.8M | $-36.0M | ||
| Q2 25 | $18.6M | $-40.7M | ||
| Q1 25 | $18.4M | $-48.4M | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $8.7M | $-41.7M | ||
| Q2 24 | $11.4M | $-80.3M | ||
| Q1 24 | $10.9M | $-53.5M |
毛利率THFFZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率THFFZLAB
| Q4 25 | 37.4% | -54.6% | ||
| Q3 25 | 39.2% | -42.3% | ||
| Q2 25 | 36.2% | -50.3% | ||
| Q1 25 | 38.1% | -53.3% | ||
| Q4 24 | 32.4% | -62.6% | ||
| Q3 24 | 17.9% | -66.6% | ||
| Q2 24 | 27.6% | -76.0% | ||
| Q1 24 | 27.2% | -80.7% |
净利率THFFZLAB
| Q4 25 | 30.4% | — | ||
| Q3 25 | 31.6% | -31.2% | ||
| Q2 25 | 29.5% | -37.3% | ||
| Q1 25 | 29.5% | -45.8% | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 15.0% | -40.9% | ||
| Q2 24 | 23.1% | -80.2% | ||
| Q1 24 | 22.6% | -61.4% |
每股收益（稀释后）THFFZLAB
| Q4 25 | $1.81 | $-0.05 | ||
| Q3 25 | $1.75 | $-0.03 | ||
| Q2 25 | $1.57 | $-0.04 | ||
| Q1 25 | $1.55 | $-0.04 | ||
| Q4 24 | $1.37 | $-0.09 | ||
| Q3 24 | $0.74 | $-0.04 | ||
| Q2 24 | $0.96 | $-0.08 | ||
| Q1 24 | $0.93 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $188.2M | — |
| 股东权益账面价值 | $650.9M | $715.5M |
| 总资产 | $5.8B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.29× | — |
8季度趋势，按日历期对齐
现金及短期投资THFFZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务THFFZLAB
| Q4 25 | $188.2M | — | ||
| Q3 25 | $170.5M | — | ||
| Q2 25 | $122.7M | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $28.1M | — | ||
| Q3 24 | $30.5M | — | ||
| Q2 24 | $108.6M | — | ||
| Q1 24 | $58.6M | — |
股东权益THFFZLAB
| Q4 25 | $650.9M | $715.5M | ||
| Q3 25 | $622.2M | $759.9M | ||
| Q2 25 | $587.7M | $791.7M | ||
| Q1 25 | $571.9M | $810.8M | ||
| Q4 24 | $549.0M | $840.9M | ||
| Q3 24 | $566.0M | $667.7M | ||
| Q2 24 | $530.7M | $704.2M | ||
| Q1 24 | $520.8M | $762.2M |
总资产THFFZLAB
| Q4 25 | $5.8B | $1.2B | ||
| Q3 25 | $5.7B | $1.2B | ||
| Q2 25 | $5.6B | $1.2B | ||
| Q1 25 | $5.5B | $1.2B | ||
| Q4 24 | $5.6B | $1.2B | ||
| Q3 24 | $5.5B | $985.3M | ||
| Q2 24 | $4.9B | $987.4M | ||
| Q1 24 | $4.9B | $988.4M |
负债/权益比THFFZLAB
| Q4 25 | 0.29× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.21× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.20× | — | ||
| Q1 24 | 0.11× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $90.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $86.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 122.5% | -21.0% |
| 资本支出强度资本支出/营收 | 5.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.21× | — |
| 过去12个月自由现金流最近4个季度 | $144.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流THFFZLAB
| Q4 25 | $90.4M | $-26.0M | ||
| Q3 25 | $26.9M | $-32.0M | ||
| Q2 25 | $12.7M | $-31.0M | ||
| Q1 25 | $21.1M | $-61.7M | ||
| Q4 24 | $60.4M | $-55.8M | ||
| Q3 24 | $23.3M | $-26.8M | ||
| Q2 24 | $8.8M | $-42.2M | ||
| Q1 24 | $12.4M | $-90.1M |
自由现金流THFFZLAB
| Q4 25 | $86.4M | $-26.7M | ||
| Q3 25 | $25.8M | $-35.0M | ||
| Q2 25 | $11.6M | $-33.9M | ||
| Q1 25 | $20.5M | $-63.2M | ||
| Q4 24 | $54.3M | $-58.4M | ||
| Q3 24 | $19.5M | $-28.2M | ||
| Q2 24 | $8.4M | $-42.9M | ||
| Q1 24 | $11.5M | $-91.1M |
自由现金流率THFFZLAB
| Q4 25 | 122.5% | -21.0% | ||
| Q3 25 | 39.2% | -30.4% | ||
| Q2 25 | 18.4% | -31.1% | ||
| Q1 25 | 32.8% | -59.9% | ||
| Q4 24 | 87.8% | -53.8% | ||
| Q3 24 | 33.5% | -27.7% | ||
| Q2 24 | 17.2% | -42.9% | ||
| Q1 24 | 23.7% | -104.5% |
资本支出强度THFFZLAB
| Q4 25 | 5.6% | 0.5% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 0.9% | 1.5% | ||
| Q4 24 | 9.9% | 2.4% | ||
| Q3 24 | 6.5% | 1.3% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 2.0% | 1.1% |
现金转化率THFFZLAB
| Q4 25 | 4.21× | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 0.68× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | 3.72× | — | ||
| Q3 24 | 2.67× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
THFF
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
